<DOC>
	<DOCNO>NCT01134562</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability single rise dos KAI-4169 hemodialysis subject secondary hyperparathyroidism .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics KAI-4169 Hemodialysis Subjects With Secondary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Subjects provide write informed consent . iPTH least 300 pg/mL ( 32 pmol/L ) great 1200 pg/mL ( 127 pmol/L ) correct calcium least 9.0 mg/dL ( 2.25 mmol/L ) Adequate hemodialysis three time per week Excepting chronic renal failure , subject judge stable medical condition base medical history , physical examination , routine laboratory test History symptomatic ventricular dysrhythmias History angina pectoris congestive heart failure History myocardial infarction , coronary angioplasty , coronary artery bypass graft within past 6 month History treatment seizure disorder Recent ( 3 month ) parathyroidectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Clinical Trial , Phase 1</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Parathyroid hormone</keyword>
</DOC>